Trials / Completed
CompletedNCT02653625
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Tobira Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cenicriviroc 150 mg | One tablet of CVC 150 mg once daily taken with food in the morning. |
Timeline
- Start date
- 2016-03-14
- Primary completion
- 2017-08-31
- Completion
- 2017-08-31
- First posted
- 2016-01-12
- Last updated
- 2018-10-01
- Results posted
- 2018-10-01
Locations
9 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02653625. Inclusion in this directory is not an endorsement.